Sparing lymph nodes during radiation may boost immune attack on rectal cancer
NCT ID NCT07674732
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This phase 2 trial compares two treatment plans for people with locally advanced rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). One group receives standard short-course radiation followed by chemotherapy. The other group receives a newer approach: radiation that spares the lymph nodes, followed by chemotherapy plus a PD-1 immune checkpoint inhibitor and bevacizumab, a drug that blocks blood vessel growth. The goal is to see if the newer combination leads to a higher rate of complete tumor disappearance before surgery or a watch-and-wait strategy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PD-1 monoclonal antibody and bevacizumab
What this could lead to
If successful, this approach could increase the chance of eliminating the tumor before surgery, potentially allowing some patients to avoid surgery altogether.
What could go wrong
This is a small, early-phase trial, so results may not apply to all patients. Adding immunotherapy and bevacizumab also raises the risk of side effects like immune reactions or bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 610655, China
Contact Phone: •••-•••-•••• Email: •••••@•••••